Over the past few decades, siRNA and miRNA have attracted a great deal of attention from researchers and clinicians. These molecules have been extensively studied from the standpoint of developing biopharmaceuticals against various diseases, including heart disease, diabetes and cancers. siRNA suppresses only a single target, whereas each miRNA regulates the expression of multiple target genes. More importantly, because miRNA are also secreted from cancer cells, and their aberrant expression is associated with tumor development and progression, they represent not only therapeutic targets but also promising biomarkers for diagnosis and prognosis.
| INTRODUC TI ON
Several lines of evidence indicate that ncRNA regulate multiple stages of life cycle, including development, differentiation and aging, through the regulation of target gene expression. [1] [2] [3] Broadly, ncRNA can be classified into two groups: small ncRNA 18-200 nt in length and lncRNA. 4 miRNA is a type of small ncRNA. The primary function of miRNA is negative regulation of their target genes at the post-transcriptional level. Specifically, miRNA induce transcript degradation or inhibition of protein translation through sequence-specific binding with the 3′UTR of their target mRNA ( Figure 1 ). miRNA also inhibit the translation or facilitate the cleavage of their target mRNA by binding to their CDS. [5] [6] [7] To date, multiple miRNA have been identified in various types of cancers, and these tumor-associated miRNA can be classified into two groups: TS-miRNA and onco-miRNA. [8] [9] [10] [11] Because miRNA are considerably smaller than proteins, they can be introduced to cells by the same techniques used for siRNA. [12] [13] [14] Consequently, the emergence of the miRNA field prompted many cancer researchers and clinicians to develop miRNA delivery strategies for the treatment of cancer patients. In this review, we summarize the major findings regarding miRNA function in tumor development, and describe recent advances in the preclinical and clinical development of miRNA delivery systems for cancer therapeutics.
| ROLE S OF MIRNA IN C AN CER B I O LO GY
The first two miRNA to be reported, lin-4 and let-7, were discovered in the nematode Caenorhabditis elegans in 1993 and 2000, respectively. [15] [16] [17] Because let-7 is conserved across animal species, from flies to mammals, and plays important roles in the various biological processes, including cancer biology, 18 it has been extensively studied. Subsequently, multiple studies have reported the roles of miRNA in cancer biology, including tumor initiation, drug resistance and metastasis.
miRNA are also important for cell-to-cell communications involved in the inflammatory response, differentiation and tumor progression. [19] [20] [21] miRNA are secreted from various types of cells through EV containing membrane proteins such as CD63, CD81 and CD9. [22] [23] [24] In the next section, we introduce the functions of TS-miRNA and onco-miRNA in relation to malignant cancer phenotypes such as tumor initiation, EMT, drug resistance and metastasis (Table 1) .
| TUMORIG ENICIT Y
Over the past decade, CSC have been identified in many common cancer types, ranging from leukemia to solid tumors. [25] [26] [27] [28] [29] [30] [31] [32] [33] The main properties of CSC, including tumor-seeding ability and therapy resistance, have been evaluated in immunodeficient mice. Specifically, CSC were isolated by cell sorting for specific markers and then transplanted into immunodeficient mice, where their tumor-seeding abilities were examined. 34 Yu et al 35 initially identified let-7 as a master regulator of the self-renewal and tumor-seeding ability of breast cancer cells. They observed a high percentage of CSC with the CD44(high)/CD24(-/ low) antigen phenotype in tumors isolated from the patients who received chemotherapy. In addition, they showed that CSC exhibited an elevated ability to form mammospheres in vitro and tumors in NOD/SCID mice. Importantly, breast CSC-enriched cells expressed much lower levels of let-7 than parental cells or in vitro differentiated progeny with the CD44(low/-)/CD24(high) antigen phenotype.
Recently, El Helou et al 36 reported that downregulation of miR-600 is significantly associated with poor prognosis in breast cancer patients. miR-600 inhibits WNT signaling, which plays an important role in CSC renewal by directly suppressing SCD1, an enzyme required for the production of active, lipid-modified WNT proteins.
Thus, miR-600 inhibits CSC renewal, resulting in suppression of tumor-seeding ability. By contrast, miR-31 promotes the tumor- 
| DRUG RE S IS TAN CE
Resistance to chemotherapy is a major obstacle for cancer therapy, and is frequently observed in patients with cancer recurrence.
The mechanisms underlying drug resistance can be classified into two main groups: (a) upregulation of drug-transporters and antiapoptotic genes; and (b) activation of survival pathways. Several studies demonstrate that miRNA are also involved in regulating these drug-resistance pathways.
In breast cancer, miR-27b regulates resistance to docetaxel, an antimicrotubule agent, through its direct target ENPP1. 9 ENPP1 promotes the cell surface localization of ABCG2, which mediates the efflux of several types of small compounds, resulting in acquisition of docetaxel resistance. Therefore, docetaxel in combination with a miR-27b mimic effectively inhibits tumor growth in an animal model of breast cancer.
In HCC, miR-221 induces sorafenib resistance through direct inhibition of caspase 3. 39 More importantly, the expression level of circulating miR-221 in serum is significantly associated with sorafenib resistance in HCC patients. In B-cell lymphoma, miR-377 promotes resistance to ABT199 (venetoclax) by directly targeting B-cell lymphoma-extra large 37. 40 Because venetoclax is a promising small compound for treatment of multiple myeloma and chronic lymphocytic leukemia, it is likely that combination treatment with venetoclax and a miR-377 inhibitor could improve patient outcomes.
In ovarian cancer, elevated expression of nc886, a non-coding RNA induced by TGF-β treatment is associated with a poor prognosis. 
| EPITHELIAL-TO -ME S EN CHYMAL TR AN S ITI ON
The EMT, a well-studied process in which epithelial cells transdifferentiate into motile mesenchymal cells, is integral for stem cell behavior and development, and it is also observed in the context of malignant tumor behaviors such as drug resistance and metastasis. 46, 47 Two recent studies showed that EMT is not necessarily required for metastasis in mouse tumor models, 48, 49 arguing that EMT is mainly associated with resistance to chemotherapy. Although the role of EMT in metastasis is not fully elucidated, these studies In addition to the intracellular miRNA, secreted miRNA are also involved in the regulation of tumor environment and metastasis. 
TA B L E 1
Classification of miRNA according to their functions suggest that EMT inhibition may improve resistance to conventional chemotherapy.
Gregory et al

| THER APEUTI C APPROACHE S BA S ED ON MIRNA REG UL ATI ON
As described above, miRNA play important roles in tumor biology and have low toxicity, as exhibited by their endogenous expression in human tissues. Thus, investigations are in progress to develop oncomiRNA antagonizing or TS-miRNA replacement systems (Figure 2 ).
The motivation for attempting to modulate miRNA expression in disease tissues is based on the concept that TS-miRNA are more highly expressed or functional in normal tissues than in tumor tissues, whereas onco-miRNA are upregulated and activated mainly in tumor tissues. Using LNA-modified oligonucleotides, a class of highaffinity bicyclic RNA analogs, miRNA can be easily detected in these tissues, and their functions can be inhibited in in vitro and in vivo studies. [70] [71] [72] In addition to LNA-mediated suppression of miRNA, TSmiRNA replacement has been attempted using miRNA mimics, viral vectors expressing miRNA, and small compounds that regulate the endogenous expression of miRNA. 14, 73, 74 Because miR-199a is the third most highly expressed miRNA in normal liver and its downregulation correlates with poor prognosis, 75 Callegari et al 76 
86
In addition to LNA treatment, miRNA sponges are also being used to inhibit onco-miRNA. miRNA sponges are artificial transcripts that contain multiple tandem high-affinity binding sites for one or more miRNA of interest. 87 Meng et al 88 developed an miRNA sponge using cssDNA. In several types of cancer, miR-9 commonly inhibits expression of tumor-suppressor genes such as KLF17, CDH1 and LASS2. A cssDNA sponge containing four miR-9 binding sites can efficiently block miR-9 function, restoring endogenous expression of KLF17, CDH1 and LASS2.
Several studies indicate that miRNA modulation is also a promising approach for cancer immunotherapy. 12 Folate receptor is more highly expressed in epithelial cancers (breast, lung, ovary and colon) and various hematological malignancies than on normal tissues. 97 To stabilize the folate-conjugated miRNA, they also modified the passive strand of miR-34a using 2′-O-methyl 
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